Efficacy and safety of ramucirumab in gastric or gastroesophageal cancer: A systematic review and meta-analysis - 21/09/24
Highlights |
• | Ramucirumab: prolongs OS, PFS, ORR and DCR. |
• | Ramucirumab: higher incidence of hypertension, bleeding and diarrhea. |
• | Age, treatment line impact efficacy: ≥60, 2nd line benefit more. |
• | Study based on latest trials, offers crucial clinical guidance. |
Abstract |
Background |
Ramucirumab is considered a potential treatment for gastric or gastroesophageal cancer; however, its safety has not been evaluated. This meta-analysis aimed to evaluate the efficacy and safety of ramucirumab for treating gastric or gastroesophageal cancer.
Methods |
The databases of PubMed, Embase, and Cochrane Library were searched through October 2023. The search focused on randomized controlled trials (RCTs) comparing ramucirumab (with or without chemotherapy) to a placebo (with or without chemotherapy) in patients with gastric or gastroesophageal cancer. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were pooled.
Results |
Seven RCTs with a total of 2613 patients were included. Compared with placebo (with or without chemotherapy), ramucirumab (with or without chemotherapy) significantly improved OS (HR: 0.90, 95% CI: 0.82–0.99, p = 0.030), PFS (HR: 0.74, 95% CI: 0.60–0.90, p = 0.003), ORR (OR: 1.39, 95% CI: 1.15–1.67, p < 0.001), and DCR (OR: 1.91, 95% CI: 1.38–2.63, p < 0.001). However, ramucirumab (with or without chemotherapy) also increased the incidence of decreased appetite (OR: 1.29, 95% CI: 1.09–1.53, p = 0.004), diarrhea (OR: 1.39, 95% CI: 1.01–1.91, p = 0.05), hypertension (OR: 3.13, 95% CI: 2.03–4.83, p < 0.00001), and bleeding or hemorrhage (OR: 2.34, 95% CI: 1.93–2.85, p < 0.00001).
Conclusions |
Ramucirumab (with or without chemotherapy) can improve OS, PFS, ORR and DCR in patients with gastric or gastroesophageal cancer. However, it may also increase the incidence of specific AEs.
Le texte complet de cet article est disponible en PDF.Keywords : Ramucirumab, Stomach neoplasms, Gastroesophageal neoplasms, Chemotherapy, Meta-analysis
Plan
Vol 48 - N° 8
Article 102466- octobre 2024 Retour au numéro
Article précédent
- Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer
- Hampig Raphael Kourie, Joseph Zouein, Ziad Zalaquett, Alain Chebly, Lewis Nasr, Fadi El Karak, Maroun Sadek, Ousama Safar, Mouin Fouani, Nizar Bitar, Kamal Kachmar, Fady Nasr, Fadi Farhat, Jawad Makarem, Joseph Kattan, Julien Taieb
- A laterally spreading tumor surrounding a barely visible appendiceal orifice
- Flore de Castelbajac, Salome Ouazana, Xavier Dray
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?